After intratumoral α-gal glycolipid injection, α-gal glycolipids insert into tumor cell membranes and α-gal is bound by anti-Gal, the most abundant natural antibody in humans, constituting 1% of immunoglobulins; the binding activates complements and cleavage peptides C5a and C3a, and then recruits inflammatory cells and APCs into the treated lesion, converting tumor cells into an autologous tumor-associated antigen vaccine. Here, GAL is linked to neoplasm.